2 not yet recruiting, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Not yet recruiting 2, Active not recruiting 1 |
Follow FLOT Chemotherapy: new trials by email Literature Review of FLOT Chemotherapy trials Research Report on FLOT Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. FLOT Chemotherapy, Durvalumab - Gastric, Esophagogastric Junction | Phase 3 | Not yet recruiting | AstraZeneca | 140 | 2026-11-30 | 2026-10-16 |
| Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer Chemotherapy - Gastric Cancer, Neoadjuvant Chemotherapy | Phase 3 | Not yet recruiting | Ruijin Hospital | 246 | 2021-09-01 | 2021-07-19 |
| Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer Durvalumab, FLOT chemotherapy - Gastrointestinal Neoplasms, Esophagogastric Junction | Phase 3 | Active not recruiting | AstraZeneca | 957 | 2020-11-17 | 2025-12-24 |
Adenocarcinoma (1) · Gastrointestinal Neoplasms (1) · Stomach Neoplasms (1)
AstraZeneca (2) · Ruijin Hospital (1)
Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Japan (1) · Netherlands (1) · Peru (1) · Poland (1) · Russia (1)
Birendra K Sah, PH D (1) · Chen Li, PH D (1) · Zhenggang Zhu, PH D (1)
PMID 35179774, PMID 35535555, PMID 35623069, PMID 40454643, PMID 42716074
2019 (1)